Summary The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.
or destroy the preformed cyclin-cdk complex (Sherr and Roberts 1995) . All the cdk inhibitors have been proposed as tumour suppressors for their ability to block the cell cycle and arrest the growth of deregulated cancer cells. Both p2] and p27 are rarely mutated in different tumour types (Shiohara et al, 1994 ; Kawamata et al, 1995) whereas p16 and p15 are frequently deleted or mutated in many tumours of different origin (Kamb et al, 1994; Nobori et al, 1994) . The p]6 gene maps on chromosome 9p21, a region associated with a frequent loss of heterozygosity in different tumours including gliomas, leukaemia, melanoma and head and neck carcinomas (Okamoto et al, 1994) .
A high frequency of homozygous deletion of p16 has been reported in human cancer cell lines derived from many different tumour types (Kamb et al, 1994; Nobori et al, 1994) . However, the incidence of mutations or deletions in primary tumours is much lower than in cell lines (Cairns et al, 1994; Spruck et al, 1994; Zhang et al, 1994) . Mutations and homozygous deletion of pl6 have been reported in melanoma, glioblastoma, pancreatic adenocarcinoma, bladder carcinoma, non-small-cell lung cancer, acute lymphocytic leukaemia, chronic myeloid leukaemia and nonHodgkin's lymphoma (Hirama and Koeffler, 1995; Sheaff and Roberts, 1995) . It was initially reported that the p16 gene was homozygously deleted in two out of seven ovarian cancer cell lines (Kamb et al, 1994) , but a lower incidence was recently found in primary tumours (Campbell et al, 1995; Rodabaugh et al, 1995; Schultz et al, 1995; Devlin et al, 1996) .
Here we report the genomic analysis ofp16 and the level of p16 expression in 42 primary ovarian cancers and, for comparison, in five human ovarian cancer cell lines. The studies were conducted in parallel with CDK4, which has been reported to be overexpressed in some tumour samples expressing normal p16 (He et al, 1994) .
MATERIALS AND METHODS Cell lines
The human ovarian cancer cell lines OVCAR-3, SW626, SKOV-3 and IGROV were grown in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS). The human ovarian cancer cell line COR, recently isolated in our laboratory, was grown in F12 Ham supplemented with 10% FCS.
Patient characteristics
Tumour samples were obtained from 42 ovarian cancer patients (21 % stage I, 10% stage II, 62% stage III and 7% stage IV). Histological types were: serous 60%, endometrioid 10%, clear cell 5%, mucinous 5% and undifferentiated 20%. Regarding the grade, 76% of the tumours were G3, 16% G2, 8% GI and 5% were borderline.
The stage and the histological grading of the primary tumours were defined according to the FIGO criteria.
Fresh tumour tissues were obtained at first laparatomy before any other treatment. The tissues were freed from necrotic, haemorrhagic and connective tissue, minced and stored at -80°C in cryotubes (Nunc) until processed. (Kamb et al, 1994; Campbell et al, 1995) . The p16 gene homozygous deletion was investigated by PCR for the ability to amplify a region of the gene compared with the ability to amplify, as an internal control, the human ,-actin gene.
The sequences of the primers used for PCR, SSCP and DNA sequencing were: p16 exon 1, sense 5'-GAAGAAAGAG-GAGGGGG and antisense 5'-GCGCTACCTGATTCCAATTC; p16 exon 2, sense 5'-ACAAGCTTCCTITlTCCGTCAT and antisense 5'-TCTGAGCTTTGGAAGCTCTC. The sequence of the primers used for multiplex PCR were p16 exon 2, sense 5'-TCTGACCATTCTGTTCTCTC and antisense 5'-AGCAC-CACCAGCGTGTC; j-actin, sense 5'-CTTCCTGGGCATG-GAGTCCT and antisense 5'-GGAGCAATGATCTTGATCTT.
These primers amplify fragments of 340, 422, 166 and 202 bp respectively; 100 ng of genomic DNA was amplified in a final volume of 50 pl of PCR Gold buffer (Perkin Elmer), containing 150 nmol of primers and 1.5 units of Ampli-Taq Gold polymerase (Perkin-Elmer). The cycles of amplification were as described previously (Kamb et al, 1994 ) and reduced to 30 in the 0-actin coamplification to maintain the amplification in the exponential phase (Campbell et al, 1995) . Samples were loaded on 4% agarose gel and visualized by ethidium bromide staining. Exon 3 (11 bp) was not analysed.
For SSCP analysis amplification conditions were the same except for the presence of 1 jCi of [32P]dCTP (Amersham). Samples were diluted 1:4 with 0.1% SDS/10 mM EDTA and further mixed 1:1 with a stop solution consisting of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol, heated for 5 min at 95°C, chilled on ice and immediately loaded on 6% acrylamide gels containing 10% glycerol. For exon 2 samples were digested with SmaI (New England Biolabs) before loading.
DNA sequencing of both strands was performed using the Sequenase PCR product sequencing kit (Amersham).
RESULTS
Forty-two ovarian primary tumours, at different malignant stage, were examined by PCR for the possibility of homozygous deletion in the p1 6 gene (exon 1 and 2). In all the tumour samples and in the five cell lines examined, the fragments of expected size for exons 1 and 2 (respectively of 340 and 422 bp) could be amplified (data not shown). In order to exclude that the amplified fragments could be due to the presence of contaminating normal cells in the tumour specimen, we performed a multiplex PCR with the ,-actin as an internal control with a reduced number of cycles (see Materials and methods). Figure 1 reports the data obtained on the 5' half of exon 2, where the majority of p16 mutations in human cancer cells have been described (Maestro et al, 1995) . Moreover, under these conditions no deletions could be found. Each tumour was examined in at least two independent experiments and small variations were observed in the relative intensities of the human P-actin and p16 bands among the experiments. Figure 2 (top). A predominant 4.3-kbp band was found after hybridization with piS c-DNA. A second, less intense band of approximately 6 kbp was found, which is likely to be cross-hybridization with p15 (Kamb et al, 1994) . All the tumour specimens presented the band of the expected molecular weight with non-significant reduction in the pieS signal compared with the control human a-actin gene (Figure 2, bottom) .
These data confirm the PCR results, suggesting that no deletions or gross rearrangements are found on the pieS gene-.
We then screened genomic DNA for point mutations in exons and 2 of the pieS gene by SSCP analysis with the same set of primers and PCR conditions (data not shown). Any suspect, differently migrating band was considered as potentially indicative of a mutation in the DNA sequence. In half (2 1) of the tumour specimens both strands of each exon were sequenced and analysed for mutations. We could not detect mutations in both exons in any of the DNA samples analysed.
We then evaluated p16 and CDK4 (p34) protein expression by Western blotting (Figure 3 ) using specific antibodies with no crossreactivity with other cdks and cdk inhibitors. The p16 protein was undetectable in 11 out of 42 patients and in three out of five cell lines (OVCAR-3, SKOV-3 and SW626), whereas the CDK4 protein was detected in all the primary tumours with a low degree of interpatient variation, and in all the five ovarian carcinoma cell lines examined.
To verify whether the lack of p16 expression in 26% (11 out of 42) of primary ovarian tumours was due to hypermethylation of the p16 gene, we digested genomic DNAs with either EcoRI and the methylation-sensitive enzyme SacII. The presence of hypermethylation in exon 1 is demonstrated by the presence of a 4.3-kbp band (which results from digestion with EcoRI alone) whereas the presence of a 3.3-kbp band is indicative of digestion with both enzymes. Figure 4 reports that in all the tumours tested the double digestion resulted in the formation of the 3.3-kbp fragment with no evidence of hypermethylation. In patient number 13 a smaller band appeared that, however, is likely to be an artefact as it was not observed in the EcoRI-digested samples (see Figure 2 ).
DISCUSSION
Activation of oncogenes and inactivation or deletion of tumoursuppressor genes are events involved in malignant transformation and tumour progression.
Recently a G, cdk inhibitor (p16) has been cloned and shown to map in a region of chromosome 9 (9p2l) frequently associated with loss of heterozygosity in different human tumour types (Okamoto et al, 1994) . The high frequency of deletion of the p16 gene in tumour cell lines strongly suggested its role as a tumoursuppressor gene and recent data reported the ability of pi6, once introduced into tumour cells, to arrest proliferation by blocking cells in G, (Jin et al, 1995; Quelle et al, 1995) .
In ovarian tumours pi6 was initially found deleted in two out of seven cell lines (Kamb et al, 1994) . More recently, however, little or no deletion of p16 in primary tumours has been observed (Campbell et al, 1995; Rodabaugh et al, 1995; Schultz et al, 1995; Devlin et al, 1996) , suggesting that pi6 abnormalities were a secondary event selected for during the establishment of cell lines (Beijersbergen and Bernards, 1996) .
In our study none of the tumours analysed presented deletion or point mutations of the pi6 gene. Our data are further supported by the finding that the analysis of ten additional human ovarian tumours transplanted into nude mice did not show evidence of deletion of p]6 (unpublished data).
Our results, together with those already published, indicate that in human ovarian carcinoma pl6 structural gene alterations are not involved in the pathogenesis of this malignancy.
No data on p16 protein expression in ovarian tumours are available. It has been reported that in human ovarian cancer cell lines retaining the p16 gene mRNA for p]6 was present (Schultz et al, 1995) . In fresh human samples down-regulation of p16 mRNA was found in only 1 out of 11 ovarian carcinomas (Rodabaugh et al, 1995) .
In the present study, we found that p16 protein was not detectable in 26% (11 out of 42) of primary tumours and in three cell lines growing in vitro. Lack of expression was not able to be correlated with the tumour stage, tumour grade or histological type.
British Journal of Cancer (1997) The inactivation of the pi6 gene transcription without altering its primary structure could be due to the methylation on the CpG islands spanning exon 1 and part of exon 2 (Merlo et al, 1995; Nishikawa et al, 1995) . This process, which appears comparable with genetic imprinting, has been found in different tumours (Beijersbergen and Bernards, 1996) that had previously shown no p16 gene modification.
In our study we found that ovarian tumours, without p 16 protein expression, did not reveal hypermethylation of pl6 promoter, and that other mechanisms, not yet identified, of p16 silencing are likely to occur. In particular, the possibility exists that a different protein resulting from an alternative reading frame usage (p1 9ad in mouse) (Beijersbergen and Bernards, 1996; Li et al, 1996) could be expressed in these patients. The lack of specific antibodies for this human alternative protein, however, did not allow us to study this possibility. An alternative way would be to analyse for the presence of alternative rmRNA in ovarian cancer patients and this is at present under investigation (the limited amount of tumour samples obtained allowed us to simultaneously analyse in the same patients only DNA and proteins). Preliminary data obtained by RT-PCR using specific primers as described (Stone et al, 1995) , however, showed that the n-transcript was present in only one of the three cell lines not expressing p16 (data not shown). A definite conclusion cannot be drawn from these results, considering the differences already observed between cell lines in culture and primary tumours at the level of mutation or deletion for the p16 gene (Spruck et al, 1994) .
It has been reported that cancer cells with normal p16 gene can overexpress and amplify CDK4 as an alternative way to interfere with cell growth regulation (He et al, 1994) . This mechanism does not seem to play a role in ovarian cancer as we found homogeneous expression of CDK4 protein either in primary tumours or in the five human ovarian cancer cell lines tested. In conclusion, the lack of expression found on p16 protein in a relatively high percentage of human tumours could be an important factor in the development of ovarian cancer.
